IAVI announcement
IAVI announced the first vaccination administered in a new cohort of participants in the IMAGINE clinical trial of the TB vaccine candidate MTBVAC. This cohort will enroll 1,200 participants who have never been exposed to Mycobacterium tuberculosis (M.tb). Individuals in this new cohort will have a negative Interferon Gamma Release Assay (IGRA) blood test that measures immune memory to M.tb. Enrollment will take place at 16 clinical research centers in South Africa, Kenya, and Tanzania.
The IMAGINE trial is a Phase 2b, large-scale efficacy trial that will test the safety and immunogenicity of MTBVAC in adults and adolescents.
MTBVAC is a single-shot vaccine delivered via intradermal delivery. It does not require an adjuvant and is well-suited for use in difficult-to-reach locations. It is the only live-attenuated TB vaccine candidate derived from M.tb in current trials. This is a notable difference from BCG, the only approved TB vaccine, which is derived from Mycobacterium bovis.
Read the full announcement here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #7, 3 March 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : IAVI
Related HIV and Co-Infections News
-
Eastleigh Voice: Ghana rejects Sh14 billion US health deal over data access concerns
-
The Lancet Global Health: Untangling the complex relationship between HIV-exposure and TB in children: A narrative review
-
Research Centre Borstel: Long-term cure rates for multidrug-resistant TB much better than expected
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.